2018-08-03IMPACT Therapeutics Raises $30 Million In Series C Financing
NANJING, China, Aug. 3, 2018 /PRNewswire/ -- IMPACT Therapeutics, Inc. (IMPACT), a China-based clinical-stage biopharmaceutical company dedicated to the discovery and development of "best-in-class" medicine for the treatment of cancer and other life-threatening diseases, today announced the completion of $30 million in series C financing.
2017-05-09IMPACT Received IMP4297 Chinese IND Approval
IMPACT Therapeutics, Inc.（(IMPACT) announced that CFDA granted approval to its IND application of IMP4297, a potential best-in-class PARP inhibitor, in January 2017. The company dosed the first patient in its Australian Phase I trial in February 2017 and has since initiated IMP4297 Phase I clinical trial in China.
2016-02-18IMPACT Therapeutics Inc. Announces Completion of around $10 Million Series B Financing
In Dec. 2015 IMPACT Therapeutics, a company dedicated to discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening disease, announced the completion of around $10 million series B financing, which will be used to advance clinical studies and development of pipeline products.
2015-01-14IMPACT Therapeutics successfully completed A round of financing
IMPACT Therapeutics is pleased to announce the closing of a round of VC financing. The VC firms include，The Lilly Asia Ventures, Cenova Ventures and WuXi AppTec Ventures, who are among the best known venture firms in the biomedical sectors in China.
2011-12-20IMS reported Impact Therapeutics in its R&D FOCUS drug news
IMSDRUGNEWS has a two-page introduction of IMPACT Therapeutics and IMPACT’s three ongoing oncology programs, in the Dec.19th, 2011(Volume 20, No.51) issue of R&D FOCUS drugnews.